BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV – Get Rating) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 55,800 shares, an increase of 206.6% from the December 31st total of 18,200 shares. Approximately 3.1% of the shares of the company are sold short. Based on an average daily volume of 142,500 shares, the days-to-cover ratio is presently 0.4 days.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of BiondVax Pharmaceuticals in a research report on Tuesday. They issued a "sell" rating on the stock.

BiondVax Pharmaceuticals Price Performance

BVXV stock traded down $0.14 on Friday, reaching $2.61. 48,048 shares of the company were exchanged, compared to its average volume of 433,073. BiondVax Pharmaceuticals has a 12 month low of $2.37 and a 12 month high of $22.90. The stock's fifty day moving average price is $5.50 and its 200 day moving average price is $8.34. The company has a current ratio of 5.76, a quick ratio of 5.76 and a debt-to-equity ratio of 5.92.

Hedge Funds Weigh In On BiondVax Pharmaceuticals

A hedge fund recently raised its stake in BiondVax Pharmaceuticals stock. Envestnet Asset Management Inc. increased its stake in shares of BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV – Get Rating) by 226.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 163,423 shares of the company's stock after acquiring an additional 113,418 shares during the quarter. Envestnet Asset Management Inc. owned about 1.44% of BiondVax Pharmaceuticals worth $191,000 at the end of the most recent reporting period.

BiondVax Pharmaceuticals Company Profile

(Get Rating)

BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza.

Featured Stories

• Get a free copy of the StockNews.com research report on BiondVax Pharmaceuticals (BVXV)
• MarketBeat Week in Review – 1/23- 1/27
• Why Lucid Spiked Nearly 100% In One Day
• Ride These Railroad Stocks for Growth and Income
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.